Niyondiko, N. (2024) Clinical Management of Diabetic Ketoacidosis in Pregnancy: A Review of Current Literature. Open Access Library Journal, 11, 1-25. doi: 10.4236/oalib.1112246 .

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Dawe, a self-proclaimed “massive foodie,” suddenly found herself unable to eat a single thing. “It was really scary – I just ...

GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-yearStrong cumulative ...

Evoke Pharma Inc. is a specialty pharmaceutical company based in Delaware, primarily focused on the development and commercialization of drugs for gastroenterological disorders, notably through its ...

It is driven by rising diabetes rates. The global gastroparesis drugs market is set to grow by $1.42b from 2024 to 2028, with ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

Gastroparesis is a chronic disorder that affects a significant subset of the population. Diabetes mellitus is a risk factor for the development of gastroparesis. Currently, metoclopramide is the ...

Braden Kuo has received funding from Evoke Pharmaceuticals to carry out clinical trials into the development of intranasal metoclopramide for diabetic gastroparesis. The authors have no other ...

Evoke Pharma shares rose 70% on Monday after presenting data on Gimoti in GLP-1 users. Shares were trading around $9 in recent trading. The stock is down more than 28% on the year so far.

Despite the recent stock surge, Evoke Pharma’s year-to-date performance tells a different story. The stock is down a notable 57.44%, starkly contrasting with the S&P 500’s impressive 21.77% gain. This ...